PURPOSE: A higher rate of comorbidities and an anticipated higher operative risk in octogenarians may influence urologists in opting for less aggressive and less effective treatment modalities for muscle-invasive bladder cancer. This study was performed to compare survival after different treatment modalities in octogenarians with stage T2 bladder cancer. METHODS: Patients that were 80 years or older with a diagnosis of transitional cell carcinoma of the bladder were identified using the Surveillance, Epidemiology, and End Results-17 registry database between 1988 and 2007. Patients were analyzed for treatment method and outcomes, including overall survival (OS) and cancer-specific survival (CSS). RESULTS: A total of 3,232 patients met inclusion criteria. Of these, 69 % (N = 2,216) underwent only transurethral resection (TURBT), 23 % (N = 733) underwent pelvic radiation therapy (RT), and 9 % (N = 283) underwent definitive surgical therapy. The 3-, 5-, and 10-year OS rates were 22.2, 15.0, and 4.4 %, respectively, for TURBT; 27.8, 18.3, and 3.5 % for RT; and 52.7, 39.1, and 17.2 % for definitive surgery. The 3-, 5-, and 10-year CSS rates were 38.3, 33.4, and 27.4 %, respectively, for TURBT; 41.6, 35.0, and 27.2 % for RT; and 66.6, 55.5, and 49.9 % for definitive surgery. Both partial and radical cystectomy had significantly longer CSS rates at 3 and 5 years when compared to RT (p ≤ 0.001). CONCLUSIONS: Compared to other treatment modalities, surgery, either radical cystectomy or partial cystectomy, offers the best OS and CSS for men aged 80 years or older with T2 bladder cancer.
PURPOSE: A higher rate of comorbidities and an anticipated higher operative risk in octogenarians may influence urologists in opting for less aggressive and less effective treatment modalities for muscle-invasive bladder cancer. This study was performed to compare survival after different treatment modalities in octogenarians with stage T2 bladder cancer. METHODS:Patients that were 80 years or older with a diagnosis of transitional cell carcinoma of the bladder were identified using the Surveillance, Epidemiology, and End Results-17 registry database between 1988 and 2007. Patients were analyzed for treatment method and outcomes, including overall survival (OS) and cancer-specific survival (CSS). RESULTS: A total of 3,232 patients met inclusion criteria. Of these, 69 % (N = 2,216) underwent only transurethral resection (TURBT), 23 % (N = 733) underwent pelvic radiation therapy (RT), and 9 % (N = 283) underwent definitive surgical therapy. The 3-, 5-, and 10-year OS rates were 22.2, 15.0, and 4.4 %, respectively, for TURBT; 27.8, 18.3, and 3.5 % for RT; and 52.7, 39.1, and 17.2 % for definitive surgery. The 3-, 5-, and 10-year CSS rates were 38.3, 33.4, and 27.4 %, respectively, for TURBT; 41.6, 35.0, and 27.2 % for RT; and 66.6, 55.5, and 49.9 % for definitive surgery. Both partial and radical cystectomy had significantly longer CSS rates at 3 and 5 years when compared to RT (p ≤ 0.001). CONCLUSIONS: Compared to other treatment modalities, surgery, either radical cystectomy or partial cystectomy, offers the best OS and CSS for men aged 80 years or older with T2 bladder cancer.
Authors: Adrian S Fairey; Niels-Erik B Jacobsen; Michael P Chetner; David R Mador; James B Metcalfe; Ronald B Moore; Keith F Rourke; Gerald T Todd; Peter M Venner; Don C Voaklander; Eric P Estey Journal: J Urol Date: 2009-05-17 Impact factor: 7.450
Authors: Elzbieta van der Steen-Banasik; Martine Ploeg; Johannes A Witjes; Farida S van Rey; Jan G Idema; Robert P Heijbroek; Herbert F Karthaus; Janny G Reinders; A Viddeleer; Andries G Visser Journal: Radiother Oncol Date: 2009-05-18 Impact factor: 6.280
Authors: H Scher; R Bahnson; S Cohen; M Eisenberger; H Herr; J Kozlowski; P Lange; J Montie; A Pollack; D Raghaven; J Richie; W Shipley Journal: Oncology (Williston Park) Date: 1998-07 Impact factor: 2.990
Authors: T Grimm; A Buchner; B Schneevoigt; A Kretschmer; M Apfelbeck; M Grabbert; J F Jokisch; C G Stief; A Karl Journal: World J Urol Date: 2015-09-16 Impact factor: 4.226
Authors: Izak Faiena; Viktor Dombrovskiy; Christopher Koprowski; Eric A Singer; Thomas L Jang; Robert E Weiss Journal: Can J Urol Date: 2014-12 Impact factor: 1.344
Authors: Pau Sarrio-Sanz; Laura Martinez-Cayuelas; Vicente Francisco Gil-Guillen; José Antonio Quesada; Luis Gomez-Perez Journal: J Clin Med Date: 2022-02-10 Impact factor: 4.241